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Recently, the tropomyosin-related kinase B (TrkB) signaling pathway has attracted much 
attention, as it has been proven to be involved in the mechanism of action of antidepressant 
drugs (Antila et al., 2017; Autry & Monteggia, 2012; Castrén & Rantamäki, 2010; Duman et 
al., 2012; Kohtala et al., 2019b; Rantamäki et al., 2011). This was a surprising finding, since 
antidepressant action had been previously linked chiefly to the brain monoamine (e.g. 
serotonin) levels. In addition, the TrkB signaling pathway has been observed to promote 
synaptic plasticity, which putatively underlies the positive antidepressant effects. According 
to previous research, the TrkB receptor is activated by its primary ligand i.e. brain-derived 
neurotrophic factor (BDNF). However, it has been determined that the TrkB receptor can be 
also activated independently of BDNF, with Src kinase being involved in the process.  
Several sedative-anesthetic drugs have been shown to alleviate depressive symptoms and 
concomitantly induce the TrkB signaling pathway. The most prominent example of these 
drugs is ketamine, which already produces its positive effects within hours of drug 
administration. The sedative-anesthetic drugs that activate the TrkB signaling pathway have 
been also shown to simultaneously induce brain slow wave EEG activity (SWA). Given that 
the TrkB pathway and SWA co-occur, it can be inferred that eliciting SWA would induce 
TrkB signaling. SWA mainly takes place during sedated state and deep sleep. Sedative-
anesthetic drugs cause sedation, thus inducing SWA. Alternatively, SWA occurs during 
deep sleep which is a physiological process. Interestingly, deep sleep can be intensified by 
implementing sleep deprivation.  Sleep deprivation increases homeostatic pressure, thus 
causing the following sleep period to be more intense than normally. Therefore, it could be 
hypothesized that sleep deprivation with subsequent recovery sleep will elicit particularly 
intensive SWA.  
In this study, we attempt to disclose the role of Src kinase in the TrkB signaling pathway 
induced by different sedative-anesthetic treatments. As a novel means to induce TrkB 
signaling, we used sleep deprivation with subsequent recovery sleep. The results were 






2. Review of the literature 
The following literature review first provides an overview of the BDNF-TrkB signaling 
pathway. It then discloses Src kinase and its possible involvement in the activation of the 
TrkB receptor. After this, the literature review discusses the concurrence SWA and 
enhanced TrkB signaling. Finally, it evaluates the possibility of inducing the TrkB signaling 
pathway by implementing sleep deprivation with consequent recovery sleep.  
2.1. An introduction to BDNF-TrkB signaling 
BDNF belongs to the family of neurotrophins. Neurotrophins control growth, maintenance 
and function of vertebrate nervous system. The first neurotrophin, nerve growth factor 
(NGF), was discovered in 1950s by Rita Levi-Montalcini, Victor Hamburger and Stanley 
Cohen. In addition to NGF and BDNF, neurotrophin family in mammals comprises 
neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) (Hallböök et al., 1991; Maisonpierre et al., 
1990). The members of the family structurally resemble each other, so much so that BDNF 
has the half of its amino acid sequence identical with NGF.  
BDNF protein was first isolated from the pig brain (Barde et al., 1982). It is produced in 
endoplasmic reticulum in a form of pro-BDNF (molecular weight 30-35 kDa), that is later 
cleaved to its mature form. Mature BDNF is much smaller than pro-BDNF, its molecular 
weight being only 13 kDa (Barde et al., 1982; Bathina & Das, 2015). BDNF is the most 
abundant neurotrophin in the brain. While BDNF is widely expressed in the brain, most 
abundant expression is seen in the cerebral cortex and hippocampus regions (Katoh-Semba 
et al., 1997). Even the areas that do not produce BDNF can contain the transported form of 
it (Antila, 2016). BDNF is present mostly in neurons, but to smaller extent also in astrocytes 
and microglia (Wetmore et al., 1990). In addition, BDNF is also present in the bloodstream, 
preferentially in the platelets, although the correlation between the brain and blood BDNF 
concentration remains unclear (Fujimura et al., 2002).  
BDNF is important for the early development of the central nervous system (CNS) in 
mammals (Huang et al., 1999; Huang & Reichardt, 2001; Thoenen et al., 1995). BDNF is 
also a chief factor in promoting the differentiation and survival of subpopulations of neurons 
in peripheral nervous system (PNS). Additionally, it is a significant promoter of maturation 
of the inhibitory interneurons. All the above-mentioned positive effects on the nervous 
system are produced upon the interaction of BDNF with its receptor TrkB.  
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TrkB serves as a receptor for BDNF and NT-4, although it has higher affinity to BDNF 
(Huang & Reichardt, 2003). It belongs to the family of Trk receptors, which includes also 
TrkA, a receptor of NGF, as well as TrkC, a receptor of NT-3. TrkB was first isolated by 
cloning from mouse brain tissue (Klein et al., 1989; Klein et al., 1990). The molecular weight 
of the full-length TrkB is 145 kDa (Saarelainen et al, 2003). The TrkB receptor has two ends: 
N-terminus facing the extracellular side and C-terminus inside the cell. The full-length 
receptor encompasses the extracellular domains, a short transmembrane domain and an 
intracellular domain, which contains tyrosine kinase domain with adjacent tyrosine (Y) motifs 
(Figure 1). BDNF binds to the extracellular domains of TrkB, namely immunoglobulin-like 
domains and leucine-rich repeats (Reichardt, 2006). Upon BDNF binding, phosphorylation 
of these cytoplasmic tyrosines takes place. Such modification adjusts tyrosine kinase activity 
and provides docking sites for adaptor proteins and enzymes that facilitate the initiation of 
intracellular pathways. In addition to the full-length receptor, also a truncated form of TrkB 
can be expressed (Antila, 2016). The truncated form resembles the full-length isoform, but 
it lacks the tyrosine kinase intracellular domain.  
Figure 1. The full-length TrkB receptor. The extracellular domain includes two 
cysteine clusters (C), leucine-rich repeats (LRR) and two immunoglobulin-like 
domains (Ig). BDNF binds to the Ig and most probably to the LRR. As a result 
of BDNF binding, the TrkB receptor forms a homodimer. The catalytic domain 
(Y705/6) is marked with a symbol of the sun. During the homodimer formation, 
two TrkB receptors approach each other and phosphorylate each other’s 
catalytic domains. Following that phosphorylation, the receptor is active and 
other intracellular tyrosine residues can be phosphorylated as well, thus 
initiating signaling cascades. Abbreviations: C1 and C2, cysteine clusters; 
LRR 1-3, leucine-rich repeats; Ig1 and Ig2, immunoglobulin-like domains 
(Figure based on that of Uren & Turnley, 2014). 
Regarding the sites of expression, TrkB is widely expressed both in CNS and PNS. In the 
brain it is produced in cerebral cortex, hippocampus, corpus callosum, hypothalamus and 
spinal cord (Klein et al., 1993; Yan et al., 1997). Thus, the common expression sites for both 
BDNF and TrkB are chiefly hippocampus and prefrontal cortex (Wetmore et al., 1990; Klein 
et al., 1993). 
BDNF-TrkB signaling is crucial for the formation and maintenance of CNS and PNS. This is 
confirmed by the fact that mice with complete deletion of BDNF/TrkB cannot survive after 
birth due to defects in the PNS (Klein et al., 1993). In addition to its recognized role in the 
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maintenance of the nervous system, the BDNF-TrkB signaling pathway was also proven to 
be intimately linked to the processes underlying neuronal plasticity and antidepressant drug 
effects (Thoenen, 1995; Saarelainen et al., 2003; Castrén & Rantamäki, 2010). As a result, 
much research in recent years has focused on the TrkB signaling pathway and its effects on 
synaptic plasticity and involvement in mood disorders and their treatment. 
2.2. BDNF-TrkB signaling regulation in neuronal plasticity 
By neuronal plasticity we understand the brain ability to adapt in response to environmental 
inputs or internal activity. Neuronal plasticity events depend on the activity of neurotrophins, 
as reviewed elsewhere (Castrén et al. 2007; McAllister et al. 1999; Thoenen, 1995). In order 
to neurotrophins underlie neuronal plasticity, they must meet the following requirements: 
neurotrophins and their receptors must be expressed in the appropriate brain areas; their 
secretion has to be activity-dependent, and they must regulate neuronal functions 
(McAllister et al., 1999). The plasticity of the brain is at its best during the critical period. The 
critical period can be defined as a “well-defined time window during which environmental 
sensory stimulus is required for proper wiring and fine-tuning of neuronal networks in the 
brain” (Antila, 2016). Only during the critical period, the brain adaptation is highly efficient, 
and once the period is over, some neural processes are irreversible.  
This brain plasticity is mainly expressed in processes such as neuro- and synaptogenesis. 
Neurogenesis and the birth of new synaptic connections are clear signs of synaptic plasticity, 
while reduced volume of hippocampus and prefrontal cortex are hallmarks of depression 
(Castrén et al., 2007). Therefore, events like neuro- and synaptogenesis, as well as neuronal 
maturation should characterize an efficient antidepressant treatment. It was determined that 
antidepressants promote the maturation of newborn neurons and support synaptogenesis 
in hippocampus (Fujioka et al., 2004). According with these findings, it was tested whether 
an antidepressant drug fluoxetine can restore neuronal plasticity in the visual cortex of rat 
(Vetencourt et al., 2008). The experiments were performed on the visual cortex, since it is a 
widespread model system for studies of activity-dependent plasticity. A common method to 
study the formation of neuronal circuits in the visual cortex is monocular deprivation. 
Monocular deprivation consists in keeping one eye covered during the critical period of 
neuronal plasticity. As a result, only the neuronal circuits of the uncovered eye develop 
properly. Vetencourt et al. implemented monocular deprivation on young rats and later 
intended to restore the visual functions of the weaker eye, a change that is ordinarily possible 
only during the critical period. As a result of the monocular deprivation, a weaker eye and 
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stronger eye were constituted. In the first experiment, fluoxetine was being administered 
and the weaker eye was kept uncovered, while the stronger eye was closed for 1-week time. 
Afterwards, the visual acuity of both eyes was compared. Intriguingly, a shift in ocular 
dominance occurred in the favor of the weaker eye. The second test was performed on adult 
rats that had become amblyopic as a result of long-term monocular deprivation. The 
experiment lasted 2 weeks and during it fluoxetine was also administered. In the test, the 
weaker eye was kept uncovered, while the stronger eye was sutured shut. As a result, the 
weaker eye recovered from amblyopia. These above-described positive effects are 
attributed to BDNF activity, since infusion of BDNF into the visual cortex essentially 
recapitulated the effects of fluoxetine. Indeed, chronic administration of antidepressants 
causes the overexpression of BDNF and its receptor TrkB. Interestingly, mRNA of BDNF in 
the visual cortex is synthesized according to activity. It was determined that light exposure 
upregulates BDNF mRNA levels in rat visual cortex, whereas light deprivation lessened the 
synthesis of BDNF (Castrén et al., 1992). Therefore, the secretion of BDNF seems to be 
activity-dependent, what confirms its role as a regulator of neuronal plasticity. Interestingly, 
BDNF has been linked to the development of visual cortex already before the study of 
Vetencourt et al. (McAllister et al., 1999; Thoenen, 1995).  
In addition to neuro- and synaptogenesis, neuronal plasticity implicates the strengthening of 
synaptic connections. The process of strengthening of synaptic connection is called Long-
Term Potentiation (LTP). LTP can be caused by either short and intensive electric impulse 
or simultaneous activation of pre- and postsynaptic neurons (Minichiello et al., 2002). It has 
been shown that LTP is a key process underlying learning and consolidation of memories in 
hippocampus (Bliss & Collingridge, 1993; Mizuno et al., 2003).  Interestingly, it has been 
discovered that BDNF enhances LTP, whereas LTP in BDNF knockout mice is considerably 
reduced (Korte et al., 1995). All in all, the neuronal plasticity-related events occur as a result 
of the activation of the TrkB receptor by BDNF.  
2.3. Activation of the TrkB receptor 
As mentioned above, the TrkB receptor is tyrosine-phosphorylated upon BDNF binding. The 
phosphorylated i.e. active form of TrkB is frequently annotated as phospho-TrkB (pTrkB). 
BDNF binds to the membrane-proximal Ig2-domain of TrkB (Reichardt, 2006). In addition to 
Ig2-domain, it seems that also Ig-1 residue may be required for the ligand binding (Huang & 
Reichardt, 2003). Most probably also leucine-rich repeats (LRR) are crucial to the binding, 
since the truncated receptor that lacks LRR is unable to bind the ligand. BDNF compels 
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TrkB to undergo a conformational change, thus producing a TrkB homodimer. The new 
dimer conformation results in an active form of the receptor (Huang & Reichardt, 2001; 
Reichardt, 2006). The homodimer is formed, when two TrkB receptors approach each other 
and phosphorylate each other’s tyrosine (Y) domains Y705/6. The Y705/6 site is the catalytic 
domain, since it is the first residue to be phosphorylated and it is required for the 
phosphorylation of additional residues.  
The most studied additional tyrosine residues of TrkB are the Y515 and the Y816 
cytoplasmic domains (Huang & Reichardt, 2001). Upon the consequent phosphorylation of 
above-mentioned tyrosine residues, new binding sites are created for adaptor proteins 
(Middlemas et al., 1994). The proteins that dock in the binding site must contain either 
phosphotyrosine-binding (PTB) or SH2 domain (Reichardt, 2006).  
Following the initiation of several intracellular cascades, the receptor itself is endocytosed 
(Huang & Reichardt, 2003). Endocytosis of the TrkB receptor most probably modulates the 
duration of TrkB signaling. It was determined that prolonged administration of BDNF 
decreases the number of the TrkB receptors located on the cell surface, due to their 
endocytosis into cytosol. It seems that the endocytosis of TrkB is stimulated by the BDNF 
binding, as well as by the increase of the concentration of cytoplasmic Ca2+, a result of the 
phosphorylation of the Y816 domain (Reichardt, 2006). In the cell, TrkB is localized to 
intracellular vesicles (Reichardt, 2006). Apparently, receptor internalization is required for 
the survival-promoting effects at least in sensory neurons (Antila, 2016). 
Although BDNF is the key ligand for TrkB, the receptor can be also activated by additional 
factors. Activation in which the activating factor does not directly bind to the extracellular site 
of the receptor is called transactivation. 
2.4. Transactivation of the TrkB receptor 
Although BDNF is the primary ligand for the TrkB receptor, the TrkB signaling pathway can 
be also induced in the absence of the neurotrophin. Transactivation occurs directly through 
the activation of intracellular cascade (Lee & Chao, 2001). Most studies on the 
transactivation of TrkB have been performed in vitro. The first agents found to transactivate 
the TrkB receptor were adenosine and pituitary adenylate-cyclase-activating polypeptide 
(PACAP) (Lee & Chao, 2001; Lee et al., 2002). These factors stimulate the TrkB receptor 
respectively through adenosine A2A receptor and PAC1 receptor, both G protein-coupled 
receptors (GPCR). Afterwards, it was shown that also adenosine agonist can transactivate 
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TrkB (Lee & Chao, 2001). In addition to adenosine and its agonists, also intracellular zinc 
can transactivate the TrkB receptor (Huang et al., 2008). In their study, Huang et al. tested 
the effects of zinc on mossy fiber-CA3 pyramid synapses. In order to do so, they applied 
high-frequency stimulation in order to elevate the intracellular zinc concentration. 
Apparently, upon high-frequency stimulation larger amounts of glutamate and zinc are 
released from the presynaptic end (Figure 2). Thus, zinc enters the postsynaptic end through 
N-methyl-D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) and voltage-gated calcium channels. Inside the 
postsynaptic site Zn2+ inhibits C-end Src kinase (Csk). Inhibition of Csk disinhibits Src 
kinase, which in turn phosphorylates the TrkB receptor. Zinc works much faster than GPCR 
ligands, since it activates TrkB with few minutes (Huang et al., 2008). The above-mentioned 
agents transactivate the TrkB receptor thus leading to intracellular signaling cascades. 
 
Figure 2. Transactivation of the TrkB receptor via Src kinase. Upon high-frequency stimulation, zinc is released 
from the presynaptic terminal to the synaptic cleft. From there it enters the postsynaptic site via NMDA and 
AMPA receptors as well as via voltage-gated calcium channels. In the postsynaptic density zinc inhibits Csk, 
thus activating Src kinase. Src kinase in turn activates the TrkB receptor, what results in intracellular signaling. 
Abbreviations: AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; Glu, glutamate; HFS, 
high-frequency stimulation; NMDAR, N-methyl-D-aspartate receptor; VGCC, voltage-gated calcium channel; 
TrkB, tropomyosin-related kinase B; Csk, C-terminal Src kinase; Zn, zinc. (Used by permission of Elsevier, 
figure from Huang et al., 2008). 
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2.5. Intracellular downstream cascades of TrkB signaling 
Following the activation of the TrkB receptor, several intracellular cascades that promote 
cell survival and neuronal plasticity can be initiated. Which signaling cascade is initiated 
depends on the tyrosine residue that is phosphorylated (Figure 3). Once phosphorylated, 
the residue recruits an adaptor protein, which in turn communicates with the next signaling 
protein. In this fashion, the signal may finally arrive to the transcription factors that modulate 
gene expression in the cell nucleus. 
The phosphorylated Y515 site (pY515) has been associated with neuronal survival and axon 
elongation (Huang & Reichardt, 2003). The domain serves as a docking site for both Shc 
and fibroblast growth factor receptor substrate 2 (Frs2). Both Shc and Frs2 promote cell 
survival and differentiation. Shc recruits phosphoinositide 3-kinase (PI3K) which 
phosphorylates Akt protein (Duman et al., 2012). Akt protein in turn phosphorylates glycogen 
synthase kinase-3β (GSK3β) and mammalian target of rapamycin (mTOR). The 
PI3K/Akt/mTOR signaling can be initiated for instance by adenosine and PACAP (Lee & 
Chao, 2001). The PI3K/Akt/mTOR intracellular cascade leads to cell survival (Takei et al., 
2004). Alternatively, also Frs2 can bind to the pY515 domain (Lee et al., 2002). In this case, 
Frs2 forms a complex with SH2 domain-containing protein tyrosine phosphatase 2 (Shp2) 
and growth factor receptor binding protein 2 (Grb2) (Easton et al., 2006). The association of 
Grb2 with Frs2 probably leads to the activation of Ras protein. Then, Ras phosphorylates 
Raf protein, which in turn upregulates extracellular signal-regulated kinase (ERK). ERK can 
influence cyclic AMP response element binding protein (CREB). Ras/ERK pathway 
regulates spinogenesis and enhances the dendrite outgrowth (Alonso et al., 2004). 
The phosphorylated Y816 domain (pY816) has been strongly linked to synaptic plasticity 
(e.g. LTP) (Korte et al., 2000; Minichiello et al., 2002). The mechanism of the cascade is the 
following: the pY816 recruits and activates phospholipase Cγ1 (PLCγ1), which hydrolyzes 
phosphatidyl(4,5)inositol bisphosphate (PIP2) to secondary messenger molecules 
diacylglycerol (DAG) and inositol trisphosphate (IP3) (Antila, 2016). Although DAG cannot 
penetrate the cytosol, it activates protein kinase C (PKC) which in turn enters the cytoplasm 
and there it activates ERK. IP3, in turn, increases intracellular calcium concentration. The 
activation of PKC and the release of Ca2+ can further activate calcium/calmodulin-dependent 
protein kinase (CaMK) and CREB. CaMK is particularly responsible for LTP, whereas CREB 
is a transcription factor that regulates the protein synthesis in the cell nucleus (Minichiello et 
al., 2002). Both CaMK and CREB are linked to synaptic plasticity. 
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Figure 3. An overview of intracellular pathways induced by BDNF-TrkB interaction. The Y515 
domain is the starting point for both PI3K/Akt/mTOR and Ras/ERK intracellular pathways that 
lead to cell survival and growth. The Y816 residue in turn activates the PLCγ1 signaling pathway 
that increases intracellular Ca2+ concentration and activates CaMK. All the pathways converge in 
CREB that directly influences gene expression and protein synthesis (Figure based on that of 
Autry & Monteggia, 2012). 
2.6. Src kinase as a mediator of TrkB signaling 
Src kinase is a ubiquitously expressed protein that is involved in important cellular 
processes, such as inflammation, cell proliferation and survival (Roskoski, 2015). It is a non-
receptor protein-tyrosine kinase that belongs to the Src family kinases (SFKs). Src family 
kinases participate in cell signaling and are critical to diverse biological processes. There 
are eleven members of SFKs in humans, divided into 3 subgroups. From the point of view 
of this study only the first group is relevant. To this group belong Src, Fyn, Yes and Fgr 
proteins. Src was the first one of those molecules to be found. Src is a small molecule of 57 
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kDa. It contains Src homology 2 and 3 (SH2 and SH3) domains, tyrosine-kinase domain, as 
well as a regulatory tail (Figure 4). The most important residues of Src are Y527, located on 
the SH2 domain, and Y416, located in the tyrosine-kinase domain. Usually, Csk keeps the 
Y527 domain phosphorylated, thus making Src kinase inactive. In order to activate Src 
kinase, one option is to decrease the activity of Csk. When the Csk activity fades, then the 
Y527 domain is gradually dephosphorylated. This facilitates the phosphorylation of the Y416 
residue which is linked to the activity of Src kinase. A phosphorylated (active) form of Src 
kinase can be marked as phospho-Src (pSrc). Src kinase is expressed in all tissues, but 
most abundantly in brain and osteoclasts, as well as in platelets. In the CNS, Src is 
abundantly present in the post-synaptic density (Huang & Reichardt, 2001).  
So far, the investigation on Src kinase has been focused on its role in cancer (Frame, 2002). 
Src protein is overexpressed in epithelial and colon cancers. Oncogenic Src initiates the 
PI3K/Akt signaling pathway that leads to tumor cell survival. It is also probable that Src 
influences cell apoptosis. In addition to its role in cancer, Src is also a crucial agent in the 
regulation of NMDA, a subtype of glutamate receptors (Wang & Salter, 1994).  In detail, Src 
enhances the current flow through NMDA receptors. This molecular event supports the 
hypothesis that Src kinase can modulate important physiological processes.  
 
Figure 4. Src kinase in both inactive and active forms. Src kinase is inactive when 
Csk activity is high, and tyrosine-527 (Y527) is phosphorylated. Alternatively, when 
Csk activity is reduced, Src kinase becomes active. The activation is facilitated by 
the gradual dephosphorylation of the Y527 and the subsequent phosphorylation of 
tyrosine-416(Y416).  (Used by permission of Elsevier, figure from Frame, 2002). 
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In addition to the above-mentioned functions, Src takes part in the transactivation of 
epidermal growth factor (EGF) (Roskoski, 2015). It is also involved in platelet-derived growth 
factor (PDGF) and fibroblast growth factor (FGF) signaling. Regarding Trk receptors, already 
in the 1990s it was hypothesized that there could be an interaction between Trk receptors 
and Src (Obermeier et al., 1994). In a research article, Obermeier et al. suggested: “we see 
the possibility of a link between the Src signaling system and the pathway triggered by 
Shc/Trk, and possibly PLCγ1/Trk, interactions. Such a cooperative signal amplification 
scenario may, in fact, be critical for the generation of a more sustained activation of PLCγ1 
and downstream signal transducers like Ras and ERK”. Later it was discovered that Src 
mediates the transactivation of TrkA receptor by adenosine in the absence of its typical 
ligand NGF (Lee et al., 2002). The same research group has found that SFKs inhibitors PP1 
and PP2 block Trk transactivation (Rajagopal & Chao, 2006). In their study they focused on 
Fyn, a member of the same subgroup as Src. Interestingly, Fyn was activated in the same 
time pattern as Trk receptors. Therefore, an association was made that Fyn is closely 
connected to Trk receptor. Eventually, it was determined that Fyn interacts with 
juxtamembrane region of Trk.  In addition, it was proposed that Src works as a mediator in 
the zinc-mediated transactivation of the TrkB receptor (Huang et al., 2008). Huang et al. 
observed that zinc activated TrkB independently of BDNF. However, zinc did not 
phosphorylate TrkB when Src kinase was inhibited with PP2. Thus, the researchers 
suggested a mechanism, in which Zn2+ inhibit Csk activity, what results in the increased 
activity of Src kinase (Figure 2). Src kinase then phosphorylates Y705/6 site of the TrkB 
receptor. In addition to the claims of Huang et al., there is more evidence that Src could be 
implicated in the activation of TrkB (Zhang et al., 2013). According to Zhang et al, Src kinase 
is a downstream of the BDNF-TrkB pathway. In their study, whenever TrkB was activated 
by BDNF, so was Src kinase. Once activated, Src kinase provided positive feedback, thus 
phosphorylating the TrkB receptor on the Y816 domain. This phosphorylation caused the 
PLCγ1 intracellular cascade, which promoted extracellular release of glutamate. 
Accordingly, inhibition of Src prevented the phosphorylation of PLCγ1 and subsequent 
glutamate release. However, the above-mentioned studies slightly differ regarding the 
mechanism of TrkB activation. Huang et al. reported transactivation, whereas Zhang et al. 
claimed BDNF being necessary in the process. What is more, the study by Huang et al. 
reported that Src kinase activates the Y705/6 domain. Zhang et al., in turn, claimed that Src 
only interacts with the Y816 domain. Notwithstanding the dissimilarities, both researchers 
agree that the phosphorylation of the TrkB receptor and Src kinase happens simultaneously. 
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In addition, both authors concluded that TrkB phosphorylation is the first molecular event, 
after which the TrkB receptor phosphorylates Src kinase which feeds back and further 
promotes phosphorylation of TrkB (Huang & McNamara, 2010; Zhang et al., 2013). Although 
there is evidence of the interrelation between TrkB and Src kinase, the detailed mechanism 
of this interaction is still debated. A putative mechanism of the TrkB-Src interaction based 
on the review of the literature is shown below (Figure 5).   
Figure 5. A putative mechanism of the function of Src kinase in TrkB signaling. Upon BDNF binding, TrkB is 
activated, thus phosphorylating Src kinase. Src kinase, in turn, further phosphorylates the domains Y705/6 
and Y816 of the TrkB receptor, thus fully activating TrkB. Such receptor activation results in the intracellular 
signaling cascades PI3K/Akt, Ras/ERK and PLCγ1. Notably, BDNF is not the unique activator of TrkB, since 
the transactivation of the receptor can be induced by additional factors such as zinc, adenosine, PACAP or 
others (Figure based on an image from Huang & McNamara, 2010). 
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3. The TrkB receptor as a target for antidepressant treatments 
3.1. Antidepressant treatments 
The first antidepressants, iproniazid and imipramine, were discovered in the 1950s (Castrén, 
2005). Iproniazid is a monoamine oxidase inhibitor, while imipramine is a type of tricyclic 
antidepressant (TCA). Both drugs were observed to increase the brain levels of monoamine 
neurotransmitters, namely norepinephrine and serotonin. Therefore, it was suggested that 
depression is caused by low concentration of mood-responsible monoamines (Schildkraut, 
1965). This theory is named monoamine hypothesis. Later, classes of drugs were developed 
which were specifically designed to increase brain monoamine concentrations. They were: 
selective serotonin reuptake inhibitors (SSRI), serotonin–norepinephrine reuptake inhibitors 
(SNRIs) and norepinephrine reuptake inhibitors (NRI). SSRI were first launched in the late 
1980s and they are widely used to this present day. As their name implies, the selective 
monoamine reuptake inhibitors prevent the neurotransmitter reuptake to the nerve endings, 
thus increasing its concentration. Although the described molecular events take place 
immediately after drug delivery, it takes several weeks until there are signs of improvement 
in patient mood (Nestler, 1998). Therefore, it appears that re-establishing serotonin levels 
does not immediately cure depression, but rather it causes its therapeutic effect by 
modulating an alternative mechanism (Ruhé et al., 2007).  
Interestingly, it was determined that the positive effect of antidepressants correlates with the 
enhancement of BDNF-TrkB signaling (Castrén, 2005; Saarelainen et al., 2003; Rantamäki 
et al., 2011). In alignment with the above findings, rodent depression models revealed that 
the expression of BDNF was suppressed. In depressed patients lowered BDNF levels could 
be also observed in the blood. What is more, low brain BDNF concentration was 
posthumously detected in suicide victims (Dwivedi et al., 2003). Unsurprisingly, higher 
BDNF levels could be observed as a result of antidepressant treatment (Chen et al., 2001; 
Koponen et al., 2005). Regarding TrkB, the receptor of BDNF, antidepressants were also 
observed to rapidly activate TrkB signaling within one hour of drug administration (Castrén 
& Rantamäki, 2010). In addition to the activation of the TrkB receptor, also the levels of 
CREB, the downstream of the TrkB signaling pathway, were upregulated as a result of 
antidepressant treatment (Rantamäki et al., 2007). Hence, it seems that BDNF-TrkB 
signaling could underlie the efficacy of antidepressant action. Indeed, antidepressants did 
not produce positive results when tested in BDNF heterozygous knockout mice or mice with 
the truncated TrkB receptor, thus highlighting the importance of BDNF-TrkB signaling in the 
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remission from depression (Monteggia et al., 2004; Saarelainen et al., 2003). Therefore, it 
seems that the restoring of a proper functioning of the TrkB pathway reverses depression.  
3.2. Antidepressant effects of sedative-anesthetics 
Anesthetics are usually used to evoke a temporary loss of awareness during medical 
operations. They produce a sedated state of unconsciousness which quickly disappears 
after drug discontinuation. In addition to this conventional use, anesthetics such as ketamine 
and isoflurane may be used as antidepressants (Antila et al., 2017; Berman et al., 2000; 
Duman et al., 2012).  
Ketamine is an NMDA receptor antagonist, which was observed to alleviate depression 
symptoms in depressed patients within hours (Berman et al., 2000; Duman et al., 2012).  
Because of the fast onset of its antidepressant effects, ketamine is also called a rapid-acting 
antidepressant (Kohtala et al., 2019b). The molecular mechanism of the action of ketamine 
is still unclear. Nevertheless, ketamine actively regulates the TrkB signaling pathway, thus 
activating transcription factors that promote synaptogenesis and synaptic plasticity. (Duman 
et al., 2012). Apparently, ketamine inhibits NMDA receptors, thus disinhibiting AMPA 
receptors and facilitating robust flow of glutamate into the nerve cell (Figure 6). In addition 
to glutamate, also Ca2+ enters the cell via voltage-gated calcium channels. The elevated 
intracellular concentration of glutamate and calcium enhances the expression and export of 
BDNF to the synaptic cleft. Consequently, extracellular BDNF binds to TrkB, thus activating 
the receptor and initiating its intracellular pathways. These pathways promote specific 
protein translation, importantly post-synaptic density protein 95 (PSD95) and glutamate-
AMPA-receptor 1 (GluR1) which are further transported to the cell surface. They are 
recruited to the cell membrane, where they induce synaptogenesis and other neuronal 
plasticity-related events. Apparently, synaptogenesis and neuronal plasticity are the events 
that underlie the positive antidepressant effect of ketamine.  
Furthermore, although not shown in the Figure 6, ketamine increases the phosphorylation 
of GSK3β (Beurel et al., 2011). This happens most probably through PI3K/Akt signaling 
(Figure 3), since it is known that Akt regulates GSK3β (Li et al., 2010). The phosphorylation 
of GSK3β results in its inhibition. GSK3β has been associated with important cellular 
processes such as cell metabolism and differentiation (Beurel et al., 2015). Interestingly, it 
was observed that ketamine does not produce its antidepressant behavioral effects in mice 
with a knock in mutation that blocks the phosphorylation of GSK3β (Beurel et al., 2011). 
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Therefore, the inhibition of GSK3β seems to be crucial event for the antidepressant action 
of ketamine. 
 
Figure 6. A putative molecular mechanism of the antidepressant actions of ketamine. Ketamine inhibits NMDA 
receptors and indirectly GABA inhibitory interneurons. This results in increased flow of glutamate into the cell 
through AMPA receptors. Additionally, also Ca2+ enters the cell through voltage-dependent calcium channels. 
As a result, BDNF is released and it binds to TrkB, thus initiating intracellular pathways such as PI3K/Akt and 
Ras/ERK that eventually lead to enhanced synaptic plasticity through synaptogenesis. Abbreviations: VDCC, 
voltage-dependent calcium channel; PSD95, post-synaptic density protein 95; GluR1, glutamate-AMPA-
receptor 1 (Used by permission of Elsevier, figure from Duman et al. 2012). 
 
Isoflurane, in a similar manner to ketamine, also activates TrkB signaling (Antila et al., 2017). 
Isoflurane is a volatile halogenated hydrocarbon. However, isoflurane promotes TrkB 
signaling independently of BDNF in conditional (CaMKII-Cre) BDNF knockout mice. This 
raises the question if BDNF required for eliciting antidepressant effects. In any case, 
isoflurane induces TrkB signaling and enhances synaptic plasticity. It was observed that as 
a result of the activation of the TrkB signaling pathway, also GSK3β and mTOR were 
activated, thus linking isoflurane activity to synaptic plasticity (Antila et al., 2017). 
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The TrkB pathway can be also activated by sedatives, such as medetomidine (Kohtala et 
al. 2019b). Medetomidine is a hypnotic-sedative agent, conventionally used for anesthesia 
of small domestic animals. It is an α2-adrenoreceptor agonist. In Kohtala’s research 
medetomidine promoted the phosphorylation of the TrkB signaling pathway-related proteins 
but failed to produce antidepressant-like response behavior in mice (Kohtala et al., 2019b). 
Intriguingly, Kohtala et al. observed a correlation between the TrkB pathway and slow brain 
waves. What is more, also ketamine was observed to induce a rebound emergence of slow 
brain EEG waves (Feinberg & Campbell, 1993). These findings suggest that the TrkB 
signaling pathway and slow brain waves are linked. Therefore, slow brain waves could be 
considered as an indicator of TrkB signaling. 
3.3. Slow wave activity and deep sleep 
By brain waves we understand the synchronized electrical activity of neuron populations. 
These waves can be measured with electroencephalogram (EEG) apparatus and are 
classified according to their frequency (Table 1). The slow brain waves or slow period 
consists in delta waves of low frequency (0.5–4 Hz) that are present through the whole brain. 
Slow brain waves take place mostly during deep sleep.  
Sleep is a fascinating process. Despite it being a daily routine for all vertebrates, the 
mechanisms underlying sleep are still unclear. However, it is commonly accepted that there 
are two processes that regulate sleep: circadian rhythm (C) and homeostatic process (S). C 
process is associated with the biological clock of the internal organs and the expression of 
sleep genes. S process in turn is related to sleep pressure, which accumulates during wake 
hours. Both processes interact to initiate and maintain sleep phenomenon. The sleep 
process is divided into two major subphases: rapid eye movement (REM) and non-REM 
(NREM). The typical sleep in human adults consists of four stages: NREM stage 1 (α 
waves), NREM stage 2 (θ waves), NREM stage 3(δ waves) and REM phase. The above-
mentioned phases form the sleep cycle. The sleep cycle lasts 90-120 minutes in humans 
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and repeats several times during the night time until waking. Different phases and the 
corresponding brain oscillations can be detected with the help of EEG apparatus. 
Table 1. Brain waves classified according to their frequency. 
 
The first NREM stage is a transient state between wakefulness and sleep (Nutt et al., 2008). 
It is abundant in alpha waves (9–12 Hz). The second NREM phase is deeper and the brain 
oscillates with theta (5–8 Hz) frequencies. Theta frequencies also occur during meditation 
or deep relaxation. The third NREM stage is the period of the greatest muscle relaxation 
and consequently, of the most efficient recovery. It is also named slow wave sleep or deep 
sleep, since it is characterized by SWA i.e. low frequency delta brain waves (0.5–4 Hz).  
3.4. Slow wave activity induced by sleep deprivation 
The duration and intensity of SWA correlates with homeostatic sleep pressure, i.e. the longer 
the hours awake, the more intense slow wave sleep becomes. One of the physiological 
processes that increase homeostatic sleep pressure is sleep deprivation. Therefore, it could 
be assumed that sleep deprivation strengthens SWA, since it increases the homeostatic 
sleep pressure. Increased sleep pressure, in turn, causes more intense deep sleep. 
Interestingly, SWA does not occur only during deep sleep, but it may also emerge in the 
state of sedation (Table 1). Accordingly, SWA should be also induced by anesthetics, since 
they cause the state of sedation. Indeed, ketamine and medetomidine were observed to 
simultaneously potentiate SWA and TrkB signaling (Duncan et al., 2013; Kohtala et al., 
2019b). SWA was even hypothesized to be a biomarker of ketamine-induced synaptic 
plasticity (Duncan et al., 2013). Therefore, it may be assumed that both SWA and TrkB 
signaling can be induced by sleep deprivation. In fact, sleep deprivation was repeatedly 
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reported to enhance the brain SWA in the recovery sleep period following sleep deprivation 
in humans as well as in rodents (Dijk et al., 1993; Farooqui et al. 1996; Huber et al., 2000).  
To summarize, Src kinase seems to activate the TrkB receptor, thus inducing the TrkB 
signaling pathway. The TrkB signaling pathway is involved in synaptic plasticity, which is 
disrupted in major depression. Consistently, antidepressants have been observed to 
activate the TrkB receptor. In addition, it has been determined that some sedative-anesthetic 
antidepressants induce not only TrkB signaling, but also brain SWA. Thus, SWA may be 
considered as a biomarker of the active TrkB signaling pathway. There are several means 
to evoke SWA, one of them being sleep deprivation which intensifies the deep sleep. 
4. Hypothesis and the aims of the study 
The hypothesis of this study is linked to the interrelation between Src kinase and the TrkB 
signaling pathway. In this study, pharmacological agents, which were recently established 
as activators of the TrkB pathway, i.e. medetomidine and isoflurane, were used (Antila et 
al., 2017; Kohtala et al., 2019b). To our knowledge, this is the first study to investigate the 
role of Src kinase in the drug-induced TrkB signaling pathway. 
Moreover, we hypothesized that Src kinase is an activator and a part of the TrkB signaling 
pathway. Accordingly, we theorized that pretreatment with Src kinase inhibitor (PP2) would 
prevent TrkB signaling despite the following treatment with medetomidine. In this way we 
could confirm that Src kinase mediates the activation of the TrkB pathway. 
In addition, we sought to reinforce the association between TrkB signaling and SWA. Recent 
studies have indicated that various antidepressants concomitantly activate TrkB signaling 
and brain SWA (Kohtala et al., 2019a; Kohtala el al., 2019b). Therefore, we applied this 
finding and performed a sleep deprivation experiment in order to induce SWA. We 
hypothesized that as a result of sleep deprivation with deep recovery sleep, both Src kinase 
and TrkB signaling will be activated. 
The general aim of this study was to assess how different treatments affect the phospho-
Src (pSrc) levels. By analysis of the results obtained from Western blot assays we aimed to 
disclose the function of Src kinase in the TrkB signaling pathway. The experiments were 





The detailed aims of the investigation were the following: 
1. To examine whether medetomidine and isoflurane activate the TrkB pathway and 
Src kinase;  
2. To assess whether Src inhibition with PP2 results in the suppression of the TrkB 
pathway;  
3. To determine whether sleep deprivation and subsequent recovery sleep can 
initiate the TrkB signaling cascade.  
 
Figure 7. An overview of the experiments performed in this study. In the initial phase of the study, both 
pharmacological (isoflurane and medetomidine) and physiological (sleep deprivation with recovery sleep) 
means were used to promote the TrkB signaling pathway which is supposedly accompanied by brain SWA. In 
the second phase of the experiments, a Src kinase inhibitor (PP2), was used to suppress TrkB signaling. 
Abbreviations: Iso, isoflurane; med, medetomidine; SWA, slow wave activity. 
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5. Materials and Methods 
5.1. Animals 
We used adult male C57BL/6 mice (Envigo RMS, Netherlands) in the experiments. The mice 
were kept in standard conditions (21°C, 12h day-night cycle). The animals had unrestricted 
access to food and water. The mice were housed in pairs. The experiments were performed 
according to the guidelines of the Society of Neuroscience and were approved by the County 
Administrative Board of Southern Finland (License number: ESAVI/9793/04.10.07/2016). 
5.2. Pharmacological treatment and the Src inhibitor experiment 
Two sedative-anesthetic drugs were tested: medetomidine and isoflurane. In the first 
treatment medetomidine was administered (0.3 mg/kg, i.p., Domitor®, Orion Pharma), 
whereas the control group was given saline injection (Kohtala et al., 2019b). Isoflurane 
(Vetflurane®, Virbac) treatment was induced in a chamber with 4% isoflurane concentration 
and maintained with 2% concentration for 30 minutes (Antila et al., 2017). The control group 
was kept in the same conditions as the treatment group, but the inhaled gas was pure 
oxygen. Afterwards, we intended to inhibit TrkB signaling induced by medetomidine by using 
pyrazolopyrimidine 2 (PP2), a commonly implemented Src inhibitor (Figure 8).  
 
Figure 8. Second phase of the experiments (the Src inhibitor experiment). The mice were 
pretreated with either PP2 or DMSO. After 30 minutes, medetomidine or saline was 
administered. 30 minutes after the administration of the treatment, the mice were sacrificed, 
the brain areas were dissected and stored in -80°C. Abbreviations: PP2, pyrazolopyrimidine 
2; Med, medetomidine; Sal, saline; DMSO, dimethyl sulfoxide; Veh, vehicle; HC, 
hippocampus; PFC, prefrontal cortex. 
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In the Src inhibitor experiment the mice were initially given either vehicle (dimethyl sulfoxide, 
DMSO, Sigma-Aldrich) or PP2 (5 mg/kg, Tocris) dissolved in DMSO (Table 2). 30 minutes 
after the first injection, medetomidine was administered to two groups, whereas the control 
animals were given saline injection. The mice were sacrificed 30 minutes after the second 
injection. 
5.3. The sleep deprivation experiment 
Since mice are nocturnal animals, they are mostly active during the night. Therefore, they 
were subjected to sleep deprivation during daytime, when their sleep pressure was 
extremely high. Immediately after the lights were turned on, sleep deprivation was initiated, 
and lasted six hours (Huber et al., 2000). The mice were kept awake by novel object 
introduction into the cage and by gentle handling (e.g. brushing) (Franken et al., 1991). After 
the established period of sleep deprivation, the mice of the first group (sleep deprivation; 
SD;) were euthanized (Figure 9). The second group of rodents (sleep deprivation and 
recovery sleep; SD+R;) had a short recovery sleep. As mentioned in the previous sections, 
the recovery sleep period following sleep deprivation abounds in SWA compared to a normal 
sleep without previous sleep deprivation. Indeed, it was observed that sleep deprivation 
causes an immediate increase in SWA, which lasts approximately 10 minutes (Huber et al., 
2000). Therefore, we applied a recovery sleep which lasted 15 minutes, in order to be sure 
that SWA took place. The animals were monitored with video camera, and the duration of 
sleep was counted on from the moment of the movement cessation. 
 
Figure 9. The design of the sleep deprivation experiment. The mice were either not sleep-
deprived (control group, not shown here), sleep-deprived (SD) or sleep-deprived with 
recovery sleep (SD+R). Abbreviations: SD, sleep deprivation; SD+R, sleep deprivation and 
recovery sleep.  
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Table 2. The reagents used in the experiments. 
Reagent Source 
Running Buffer  





Stripping buffer  
3 M of Tris-HCl 41.6 ml; 
20% SDS 200 ml; 
Milli-Q water 2000 ml; 
β-mercaptoethanol 350 μl; 
Uni. Helsinki 
Blocking buffer 
3% BSA in TBS-T; 
Uni. Helsinki 
NP lysis buffer 
3 M Tris-HCl 670 μl; 
5 M NaCl   2.74 ml; 
0,5 M NaF 9.6 ml; 
TritonX (0.5%) 1 ml; 
Milli-Q water    ad. 100 ml; 
Uni. Helsinki 
NP ++ lysis buffer  
NP lysis buffer; 
PierceTM Protease inhibitor tablet; 





DC Protein assay reagents BioRad 
Laemmli sample buffer (2x) BioRad 
BSA protein standards BioRad 
WB detection substrate 
PierceTM ECL Plus Western Blotting kit 
 
Thermo Scientific 
Isoflurane (Vetflurane) Virbac 
DMSO Sigma-Aldrich 
PP2 Tocris 
Medetomidine (Domitor) Orion Pharma 
PVDF membrane (Amersham Hybond) GE Healthcare 
SDS-PAGE gel 
NuPAGETM 4-12% Bis-Tris Gel 












5.4. Sample Collection and Protein measurement 
At the indicated times, the animals were euthanized by rapid cervical dislocation followed 
by decapitation. The brain was quickly removed and put on a plate with ice-cold phosphate-
buffered saline (PBS). The hippocampus and the prefrontal cortex were rapidly dissected 
on the cold plate and stored at -80°C. Few days later, the brain samples were taken out of -
80°C and placed on ice. They were covered with NP++ lysis buffer and then homogenized 
with a sonicator (Rinco Ultrasonics GM 35-400, Switzerland). The samples were incubated 
on ice for 15 minutes and centrifuged (16100g, 15 min, +4°C). Supernatant was carefully 
collected and transported to another set of Eppendorf tubes. From each lysate a volume of 
5 μl was isolated for the further protein determination.  
Protein concentrations from the brain samples were measured using a revised version of 
Lowry protein measurement method i.e. DC protein assay (Lowry et al., 1951). In this 
method, protein concentration can be deduced from a standard curve which is constructed 
from bovine serum albumin (BSA) protein standards. In this way an equation is obtained 
and based on this, the protein concentration of a sample can be determined. The samples 
and protein standards were pipetted into a 96-well SpectraPlate. Then the plate was placed 
on a platform rocker for 10-15 minutes. Afterwards, the absorbance of each well at 750 nm 
was measured with absorbance reader (Biotek ELx800). The higher the absorbance of a 
lysate, the higher its protein concentration. Once determined the protein amount in the 
lysate, the volume needed for SDS-PAGE was calculated. The amount of total protein in 
each sample was 40 μg.   
5.5. SDS–PAGE and Western blotting 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) is a method used 
to separate proteins according to their molecular weight. The volumes corresponding to 40 
μg of total protein amount were mixed with 2x Laemmli buffer in 1 to 1 ratio. Laemmli buffer 
contains SDS, an agent that denatures the proteins and gives them a negative charge. The 
samples were then kept in 100°C for 3 minutes in order to ensure the denaturation of the 
proteins. Then the samples were cooled on ice and loaded onto a polyacrylamide gel, each 
sample into a separated well. In addition to the samples, a protein standard (BioRad 
Precision Plus Protein™ Dual Color) solution was loaded into the gel, so that in the detection 
step the molecular weight of each protein could be easily identified by comparing with the 
standard. The gel was put into a chamber with running buffer. The gel electrophoresis was 
performed at 180 V for 1 hour. During electrophoresis, the electric current transports the 
24 
 
proteins according to their molecular weight across the gel. One end of the gel has negative 
charge, while the other end has a positive charge. The positive end attracts the negatively 
charged proteins. The smaller the protein, the further it will migrate through the gel pores. 
Electrophoresis completed, a wide spectrum of separated protein bands is obtained.  
Electrophoresis was followed by a protein transfer onto a polyvinylidene difluoride (PVDF) 
membrane. The principle of the protein transfer is the same as that of the electrophoresis: 
the negatively charged proteins are migrating towards the positive electrode. Thus, the 
proteins bands from the gel are transferred onto a membrane. The transfer is performed by 
inserting the gel on top of the PVDF membrane. This system is then secured and put into a 
chamber filled with transfer buffer. Since plenty of heat is produced during the protein 
transfer, a small ice box was placed inside the chamber and the whole system was put inside 
a box filled with ice. Then the proteins were transferred at 300 mA for 1 hour. Once 
transferred, specific phosphorylated protein domains can be indirectly detected from the 
membrane.  
In this study we implemented indirect detection in which two types of antibodies are used: a 
primary antibody that is specific to the protein of interest, and a secondary antibody, which 
detects the presence of the primary antibody as well as the target protein. The secondary 
antibody used in this study was coupled to horseradish peroxidase (HRP), which is an 
enzyme and a reporter molecule commonly used in immunoblotting. HRP catalyzes a 
chemiluminescent reaction that produces visible light, which can be detected by a digital 
imager. The substrate (PierceTM ECL Plus) used in the chemiluminescent reaction was 
converted into acridinium ester intermediates by HRP enzyme. Then, acridinium ester 
intermediates reacted with peroxide, thus producing chemiluminescence. The amount of 
luminosity obtained from a protein band correlates with the amount of the protein. The 
membranes were placed in a small box and equilibrated in Tris-buffered saline (TBS). Then 
they were blocked with the 3% BSA in TBS-Tween 20 (TBS-T) solution for 1 hour to prevent 
nonspecific binding of the antibodies. Then the membranes were incubated overnight in the 
primary antibody solution (Table 3) on a platform rocker at -4°C. Next morning the 
membranes were washed in TBS-T for 40 minutes for the purpose of minimizing background 
signal. The washing step was followed by incubation in HRP-coupled secondary antibody 
(room temperature, 1 h). After the incubation, the washing step in TBS-T was repeated. 
Finally, the membranes were incubated in ECL Plus Western Blotting Substrate for 3 
minutes. In order to measure the intensity of the emitted light, images were taken using the 
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digital imager (BioRad ChemiDoc™ MP System), immediately after the incubation in ECL 
substrate. Finally, the protein bands from the images were quantified using Image J 
Software (ImageJ 1.46v, National Institute of Health, USA). 
Table 3. Antibodies used in the experiments. 
Antibody Host Solution Dilution Producer 
pGSK3β S9 Rabbit 3% BSA in TBS-T + NaN3 1:1000 Cell Signaling 
Technology (CST) 
pSrc Y416 Rabbit 3% BSA in TBS-T + NaN3 1:1000 CST 
pTrkB Y816 Rabbit 3% BSA in TBS-T + NaN3 1:1000 CST 
TrkB Rabbit 3% BSA in TBS-T + NaN3 1:1000 CST 
GAPDH Rabbit 3% BSA in TBS-T + NaN3 1:1000 CST 






5% NFDM in TBS-T 1:10000 BioRad 
In this study, the level of phosphorylation of the proteins involved in the TrkB pathway 
(pTrkBY816 and pGSK3βS9) was determined. These proteins were chosen on account of their 
phosphorylation being a hallmark of a positive antidepressant effect (Duman et al., 2012; 
Kohtala et al., 2019a; Rantamäki et al., 2007). In addition, we checked the levels of pSrcY416, 
in order to assess whether there is a positive correlation between the TrkB-related proteins 
and Src activation. The same, above-mentioned procedure was repeated, and the luminosity 
value was calculated for the corresponding total protein amounts i.e. TrkB and GSK3β. 
GAPDH housekeeping protein was used as a loading control for pSrcY416. The levels of the 
proteins of interest were normalized to the total amount of corresponding proteins. 
5.6. Statistical analysis 
Statistical analysis and drawing of the graphs were performed using Prism 8.1.1 (GraphPad 
Software Inc). For the majority of the analyses Student’s unpaired t-test was used (for 
experiments with two treatment groups). The Mann-Whitney U-test was implemented for 
pSrc analysis in isoflurane treatment, since the variation of results was higher compared to 
the results of other experiments. In the experiments that involved more than two treatment 
groups i.e. sleep deprivation and the Src inhibitor experiment, the ordinary one-way analysis 
of variance test was used for the analysis. The results are presented as mean ± SEM. P-




6.1. Medetomidine upregulates pSrc and pTrkB levels 
Medetomidine (0.3 mg/kg; n = 4) was administered to the mice by an intraperitoneal injection 
(i.p.). Control group (n = 4) was given a saline injection. After 30 minutes, the mice were 
sacrificed, and the prefrontal cortex samples were carefully collected and cooled on the ice. 
TrkB and Src phosphorylation were examined in a Western blotting assay as described in 
the Materials and Methods section. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was used as a loading control for pSrc in all the performed Western blotting assays, since it 
is a ubiquitously and stably expressed protein. Regarding pTrkB, it was normalized against 
the corresponding total protein amount. Compared to the control group, medetomidine 
produced clear phosphorylation effects on Src kinase (p = 0.0034) and the TrkB receptor (p 
= 0.0351) (Figure 10).  
 
Figure 10. Src and TrkB phosphorylation in the prefrontal cortex 30 minutes after the intraperitoneal injection 
of medetomidine (n = 4; 0.3 mg/kg) in mice. Control group (n = 4) was given a saline injection. The graph 
shows high phosphorylation levels in the Y416 domain of Src kinase (p = 0.0034) and the Y816 domain of the 
TrkB receptor (p = 0.0351). Western blotting results can be seen on the right. pSrc was normalized against 
GAPDH, whereas pTrkB was normalized against the corresponding total protein amount. Unpaired Student’s 
t-test was used in both cases; asterisk indicates statistical significance *p < 0.05, **p < 0.01. The data are 




6.2. Isoflurane enhances the phosphorylation of Src and TrkB proteins 
The mice were exposed to volatile isoflurane (4% during the induction and 2% during the 
maintenance; n = 6) for 30 minutes. The control group (n = 5) was also kept in the anesthesia 
chamber for 30 minutes, but the animals inhaled pure oxygen. Compared to the control mice, 
isoflurane robustly activated (p = 0.0303) the Y416 domain of Src kinase after a 30-minute 
isoflurane anesthesia (Figure 11). The Y816 domain of TrkB was also significantly 
phosphorylated (p = 0.0040), even more than in the case of medetomidine treatment.  
   
Figure 11. Isoflurane anesthesia (4% -> 2%, 30 min, n = 6) induces Src and TrkB phosphorylation in the mouse 
hippocampus. The graph shows high phosphorylation levels of the Y416 domain of Src kinase (p = 0.0303) 
and of the Y816 domain of the TrkB receptor (p = 0.0040). Control group (n = 5) was also kept in the anesthesia 
chamber but inhaled pure oxygen. pSrc was normalized against GAPDH, whereas pTrkB was normalized 
against the corresponding total protein amount. Unpaired Student’s t-test was used for pSrc, while the Mann-
Whitney U-test was implemented for pTrkB; asterisk indicates statistical significance *p < 0.05, **p < 0.01. The 
data are represented as a group mean + SEM of protein band intensities. Abbreviations: Ctrl, control treatment; 
Iso, isoflurane treatment. 
 
6.3. The Src inhibitor did not suppress TrkB signaling 
The experiment had three treatment groups in total: control group which received saline 
(Veh; 0.3 mg/kg, n = 4), medetomidine group (Med; 0.3 mg/kg, n = 4) and the inhibitor group 
that received both PP2 and medetomidine (PP2 + Med, n = 4). Medetomidine was chosen 
to the experiment due to its confirmed ability to activate Src kinase. The groups were 
pretreated either with DMSO (Veh and Med) or PP2 (PP2 + Med). The levels of pSrc were 
slightly elevated for the PP2 + Med mice both in the prefrontal cortex and the hippocampus, 
compared to the control animals (Figure 12). The same statistically non-significant results 
can be seen in the levels of pSrc for the group only treated with medetomidine. 
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Regarding pTrkB and pGSK3β, there were no major differences between different treatment 
groups. Results of this study were not consistent with those of previous research, where 
PP2 attenuated the phosphorylation of Src. In this study, PP2 did not inhibit Src kinase. 
 
Figure 12. The Src inhibitor (PP2) did not inhibit the TrkB signaling pathway. (A) Effects on the phosphorylation 
of Src, TrkB and GSK3β proteins in the adult mouse prefrontal cortex after the Src inhibitor experiment. (B) 
Phosphorylation of Src, TrkB and GSK3β in the adult mouse hippocampus after the Src inhibitor experiment. 
The animals were divided into 3 treatment groups: saline group (Veh; 0.3 mg/kg; n = 4), medetomidine 
treatment (Med; 0.3 mg/kg) and the Src inhibitor treatment (PP2 + Med; 5 mg/kg + 0.3 mg/kg; n = 4). Groups 
Veh and Med received DMSO (5 mg/kg, i.p.; n = 4) instead of PP2. The representative Western blot protein 
bands can be seen below each corresponding graph. Band intensities were normalized against GAPDH (pSrc) 
or against their correspondent total protein values (pTrkB and pGSK3β). One-way analysis of variance was 
implemented for the analysis of the results. Abbreviations: Veh, vehicle group; Med, medetomidine group; PP2 




6.4. Effects of sleep deprivation on Src, TrkB and GSKβ 
The sleep deprivation experiment involved two trial groups and one control group. The first 
trial group (sleep deprivation; SD; n = 10) was sleep deprived for 6 hours. The second group 
(sleep deprivation and recovery sleep; SD+R, n = 10) was sleep deprived for 6 hours and 
then allowed to sleep for 15 minutes. The control group (Ctrl; n = 10) was kept in a different 
room and could sleep without restrictions during the corresponding time. Western blotting 
results showed that the levels of all specific phospho-proteins (pSrc, pTrkB and pGSK3β) 
were slightly upregulated in both the prefrontal cortex and hippocampus in the group that 
had recovery sleep (Figure 13). 
 
Figure 13. Sleep deprivation slightly upregulates the TrkB signaling pathway-related phosphoproteins. (A) The 
levels of pSrc, pTrkB and pGSK3β are upregulated in the mouse prefrontal cortex. The results have been 
normalized against GAPDH (pSrc) or corresponding total protein value (pTrkB, pGSK3β). (B) The results of 
sleep deprivation in the mouse hippocampus. All the phospho-protein levels were higher in SD+R mice 
compared to the control or SD group. Band intensities of pSrc and pTrkB were both normalized against 
GAPDH, whereas pGSK3β band was normalized against its corresponding total protein value. Results are 
presented as mean + SEM of protein band intensities. (Unpaired Student’s t-test) Abbreviations: PFC, 




7. Discussion and Conclusions 
The general aim of this study was to assess how different treatments affect pSrc and the 
TrkB pathway-related phospho-protein levels. Different treatments were applied i.e. 
isoflurane and medetomidine, Src kinase inhibitor (PP2) as well as sleep deprivation with 
recovery sleep. Afterwards, the mouse brain samples were examined with Western blotting 
and checked for the presence of the proteins of interest.  
The results from the first experiment, the pharmacologically induced TrkB pathway, were 
consistent with those of previous research (Antila et al., 2017; Kohtala et al., 2019b). A 
notable upregulation of pSrc and pTrkB was observed. In particular, isoflurane treatment 
enhanced the phospho-protein levels in the mouse hippocampus, whereas medetomidine 
caused a strong response of the same phospho-proteins in the mouse prefrontal cortex. 
Both medetomidine and isoflurane simultaneously activated Src kinase and the TrkB 
receptor. No increase in phospho-protein levels was observed in the control groups. Our 
results support the hypothesis that Src kinase is closely linked to the TrkB activation, since 
both proteins were phosphorylated in the experiment. 
Earlier research has confirmed PP2 as a powerful Src kinase inhibitor (Huang et al., 2008; 
Huang & McNamara, 2010; Zhang et al., 2013), but the results obtained in this study were 
slightly disappointing in this regard. Namely, a minor, non-significant phosphorylation of Src 
occurred despite the pretreatment with PP2. Furthermore, the levels of pTrkB and pGSK3β 
proteins in the treatment group resembled those of the control group, i.e. there was no visible 
effect of PP2 pretreatment. Surprisingly, even the medetomidine-treated group exhibited 
only a small, non-significant upregulation of pSrc, although in the medetomidine experiment 
it was much more robust. Therefore, the interpretation of the results is slightly challenging. 
The failed inhibition of Src kinase might have been due to the effects of DMSO that could 
be observed during the experiment. Interestingly, we observed that mice that received both 
DMSO and medetomidine treatment became sleepy and motionless after the injection. 
Thus, it seemed like DMSO caused a state of sedation in animals. This state of sedation 
could interfere with TrkB signaling. One way to avoid this in the future could be by 
implementing a different Src kinase inhibitor that would not need dissolution in DMSO. 
Alternatively, future experiments could be performed with PP2, but in this case the doses of 
DMSO should be much lower in order not to sedate the animal. Another possibility would be 
to implement an inert vehicle. Future research should include an improved version of the 
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Src inhibitor experiment in order to determine, whether Src kinase is essential for the TrkB 
pathway. 
In this study, we hypothesized that by inducing SWA we would also activate TrkB signaling 
(Kohtala et al., 2019b). According to the literature, SWA appears to be particularly intensive 
during the immediate sleep period after sleep deprivation (Franken et al., 1991; Huber et al., 
2000). Therefore, in this study we implemented sleep deprivation combined with recovery 
sleep as a means to enhance SWA and, in consequence, TrkB signaling. Our results from 
the sleep deprivation experiment showed a clear trend: the levels of the TrkB pathway-
related phospho-proteins in the sleep-deprived and then -recovered mice were upregulated, 
without the statistical significance, compared to the other groups. In addition to a positive 
trend in Src and TrkB, the phosphorylation levels of GSK3β were also elevated. As stated 
in the literature, high phosphorylation levels of TrkB and GSK3β are associated with the 
action of rapid-acting antidepressants (Duman et al., 2012; Kohtala et al., 2019a). In this 
study, we saw a clear, although statistically non-significant trend in the activation of TrkB 
both in the prefrontal cortex and hippocampus after the recovery sleep. Therefore, it could 
be inferred that sleep deprivation with recovery sleep induces TrkB signaling. Regarding the 
group of sleep-deprived mice without recovery sleep, the phosphorylation levels of the TrkB-
related proteins were equal to those of the control group. Hence, it seems that the TrkB 
signaling pathway is only activated during slow wave sleep and not during waking hours. 
Although our results were statistically non-significant, it must be observed that sleep 
deprivation is a highly variable physiological phenomenon. Such phenomenon depends on 
the individual sleep differences between animals, such as duration and intensity of deep 
sleep. Conversely, the pharmacological treatment (medetomidine and isoflurane) 
implemented in the first experiment is more predictable, and thus it produced statistically 
significant results. It is because the same drug doses reliably produce similar effects in each 
animal. Thus, the results obtained from pharmacological treatment were naturally less 
variable than those attained in the sleep deprivation experiment. Intriguingly, we have 
recently reproduced the Western blotting analysis and observed that the pGSK3β levels 
were significantly higher in the brain samples of sleep-deprived mice with recovery sleep 
compared to the control group (Rosenholm et al., unpublished data). Therefore, it is possible 
to obtain statistically significant results from the sleep deprivation experiment.  
Despite the good results we obtained, the sleep deprivation experiment could be further 
improved. Namely, a video camera used for surveillance was not enough to ensure the equal 
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amount of sleep for each animal. Each mouse did not necessarily fall asleep immediately. It 
was challenging to determine the exact moment of falling asleep. In this study, the duration 
of recovery sleep was measured from the cessation of mouse movement, but the lack of 
movement did not undeniably mean that the animal had fallen asleep. Therefore, the 
surveillance method in future experiments could involve EEG recordings. Such recordings 
can detect SWA and thus the duration of deep sleep would be precisely measured. Another 
way to improve the sleep deprivation experiment could be the extension of recovery sleep 
duration to 30 minutes. Recovery sleep of 15 minutes duration might not be sufficient for 
animals to experience SWA, due to the delay in falling asleep for some animals. Our results 
encourage further sleep deprivation experiments in order to elucidate the TrkB pathway-
linked molecular mechanisms behind this phenomenon. 
Huang & McNamara suggested in 2010 that there are two types of TrkB activation. The first 
one is transactivation, in the absence of BDNF, where Src kinase is upstream in this 
molecular cascade. In this activation, the phosphorylation of the Y705/6 TrkB domain is the 
initial event and it is mediated by Src kinase. Once the catalytic site of TrkB is activated, the 
Y515 domain is also phosphorylated by the TrkB receptor itself. The second option for TrkB 
activation is the one mediated by prototypic ligand BDNF. In this model, BDNF 
phosphorylates the Y416 domain of Src through the initial activation of TrkB, demonstrating 
Src to be downstream of TrkB. However, in this case, Src kinase is also upstream of TrkB 
since once activated, it further phosphorylates TrkB, thus fully activating it. Interestingly, 
Zhang et al. later confirmed the second model of Huang & McNamara, namely the BDNF-
induced TrkB pathway. In this model, Src kinase is a downstream molecule for TrkB. Src 
kinase phosphorylates the Y816 domain of the TrkB receptor, which results in further TrkB 
activation.  In this study, the data we collected do not allow confirmation of the hypothesis 
of Zhang et al., since we did not check the BDNF levels. Nevertheless, our findings support 
the hypothesis that the activation of Src and TrkB is coupled, i.e. Src kinase and TrkB closely 
interact and mutually depend on each other. However, it is challenging to determine, which 
of the two molecules is upstream of the other.  A study with conditional BDNF knockout mice 
could be the next step to confirm the mechanism of TrkB activation.  
In summary, our findings support the hypothesis that Src works as a mediator of the TrkB 
signaling pathway, although further investigations are needed in order to confirm the detailed 
role of Src kinase. Our study indicates that medetomidine and isoflurane treatment initiates 
coupled activation of Src kinase and the TrkB pathway. In addition, the results obtained in 
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the sleep deprivation experiment provide support for the TrkB signaling pathway being 
induced during slow wave sleep. It would be beneficial to continue the research into sleep 
deprivation and its implications for TrkB signaling. Although the role of Src kinase in the TrkB 
pathway is still debated, if Src kinase is necessary for the TrkB pathway, it could be applied 
in future antidepressant treatment. Future research in this field should eventually lead to the 
discovery of more effective antidepressants. 
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